Loading clinical trials...
Loading clinical trials...
Pilot Study of the Safety and Efficacy of Anti-FLT3 Chimeric Antigen Receptor Engineered T-Cells in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
Conditions
Interventions
anti-FLT3 CAR-T
Locations
1
China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Start Date
December 31, 2021
Primary Completion Date
June 30, 2023
Completion Date
June 30, 2025
Last Updated
December 30, 2021
NCT06285890
NCT06220162
NCT04065399
NCT04628026
NCT06994676
NCT06484062
Lead Sponsor
The First Affiliated Hospital of Soochow University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions